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Abstract  1 
The alpha(α)2-agonist detomidine is used for equine sedation with opioids such as methadone. 2 
We retrieved the data from two randomised, cross-over studies where methadone and 3 
detomidine were given intravenously alone or combined as boli (STUDY 1) (Gozalo-Marcilla 4 
et al., 2017) or as a 2-hr constant rate infusions (STUDY 2) (Gozalo-Marcilla et al., 2019a). 5 
Plasma drug concentrations were measured with a validated tandem Mass Spectrometry assay. 6 
We used Non-Linear Mixed Effect Modeling and took PK data from both studies to fit 7 
simultaneously both drugs and explore their non-linear kinetics. Two significant improvements 8 
over the classical mammillary two-compartment model were identified. First, the inclusion of 9 
an effect of detomidine plasma concentration on the elimination clearances of both drugs 10 
improved the fit of detomidine [Objective Function Value (OFV): -160] and methadone (OFV: 11 
-132) submodels. Second, a detomidine concentration-dependent reduction of distributional 12 
clearances of each drug further improved detomidine (OFV: -60) and methadone (OFV: -52) 13 
submodel fits. Using the PK data from both studies i) helped exploring hypotheses on the non-14 
linearity of the elimination and distributional clearances, ii) allowed inclusion of dynamic 15 
effects of detomidine plasma concentration in the model which are compatible with the 16 
pharmacology of detomidine (vasoconstriction and reduction in cardiac output). 17 
 18 
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 21 
Short communication 22 
Alpha(α)2-agonists and opioids such as detomidine and methadone are commonly combined in 23 
equine standing surgery to provide sedation and analgesia. Methadone and detomidine have 24 
been administered intravenously (i.v.) as a bolus for short-term procedures (Gozalo-Marcilla 25 
et al., 2017) or as constant rate infusions (CRIs) for prolonged surgeries (Gozalo-Marcilla et 26 
al., 2019a,b).  27 
In a previous pharmacokinetic (PK) analysis after bolus administration (STUDY 1), 28 
there was evidence of interaction between the two drugs as fitting standard mammillary multi-29 
compartment (Fig 1a) was unsatisfactory (Gozalo-Marcilla et al., 2018c). Indeed, non-linear 30 
PK was considered, as for different detomidine doses there was a non-proportional change in 31 
the detomidine and methadone concentrations. Non-linearity can be explained by dose-32 
dependent alteration of drug excretion or saturation of drug metabolism (Gabrielsson et al., 33 
2016). In STUDY 1, the model including non-linearity on the elimination clearance (Cl) (Fig 34 
1b) still over-predicted detomidine concentrations when administering low doses and under-35 
predicted detomidine concentrations when administering high doses (Gozalo-Marcilla et al., 36 
2019c). In a subsequent PK/PD study with the same group of horses (STUDY 2) (Gozalo-37 
Marcilla et al., 2019a), the pharmacodynamics (PD) of methadone/detomidine combinations 38 
as CRIs were reported, but not the PK data. Non-linearity was also suspected as the ratio 39 
𝐴𝑟𝑒𝑎 𝑈𝑛𝑑𝑒𝑟 𝑡ℎ𝑒 𝐶𝑢𝑟𝑣𝑒 (𝐴𝑈𝐶)
𝑑𝑜𝑠𝑒
 was 30% higher with the high detomidine dose compared to the low 40 
dose. We hypothesised that combining the two PK datasets (STUDIES 1 & 2) would enable a 41 
better characterisation of the non-linearity on the clearance and the distribution associated with 42 
different detomidine doses. This report proposes a Michaelis-Menten equation solution to 43 
improve the fit of the observed non-linear elimination of both drugs.  44 
We used data previously collected from 8 healthy adult horses (4 males, 4 females) 45 
receiving detomidine/methadone combinations (Table 1), in two crossover studies within a 2-46 
year period. In STUDY 1, each horse received an i.v. bolus of detomidine alone, methadone 47 
alone or different combinations of both drugs. In STUDY 2, each horse received each of the 48 
following 4 treatments: i.v. bolus followed by a 2-hr CRI of detomidine (high and low dose), 49 
with detomidine alone or combined with a 2-hr CRI of methadone. For both studies, at least 50 
one week’s washout period was allowed between treatments.   51 
Venous blood was sampled from one designated jugular vein at predetermined time-52 
points, between 0 and up to 360 minutes after treatment administration. Plasma detomidine and 53 
methadone were measured with a single and validated analytical method comprised of a liquid-54 
liquid extraction technique with ethyl acetate for sample preparation and analysis by tandem 55 
Liquid Chromatography/Mass Spectrometry (Gozalo-Marcilla et al., 2019c).    56 
Our working hypothesis was that one can model the plasma concentration-time profile 57 
of both drugs by including a specific relationship between PK parameters (Cl and inter-58 
compartmental Cl) and concentration. The same non-linear mixed effect approach to PK 59 
modelling reported by Gozalo-Marcilla et al. (2019c) was used to analyse jointly the pooled 60 
plasma concentration time-curves of the two studies. We modelled the PK for both drugs 61 
together using a sequential approach; we solved the PK of detomidine first, then fixed 62 
parameter estimates (theta) and, if applicable, individual deviations (etas) before solving 63 
methadone PK employing the same principles. A proportional error model was used. Inter-64 
individual variability was estimated when enough information was available and eta shrinkage 65 
was kept to an acceptable level. Rival population PK models were designed to best fit the data 66 
and their performances were compared with Phoenix NLME 8.0 for visual inspection 67 
(goodness of fit plots) and statistically significant reduction in Objective Function Values 68 
(OFV).  69 
Dose-dependent Cls (Fig 1b) were written according to equations 1a and 1b, 70 
respectively (as in Gozalo-Marcilla et al., 2019c): 71 
𝐶𝑙𝑑𝑒𝑡𝑜𝑚𝑖𝑑𝑖𝑛𝑒(𝑐) =  𝐶𝑙𝑑𝑒𝑡𝑜𝑚𝑖𝑑𝑖𝑛𝑒_𝑏𝑎𝑠𝑎𝑙  × (1 − 𝑆 × (log (1 + [𝐷𝑒𝑡𝑜𝑚𝑖𝑑𝑖𝑛𝑒]) )    Eq 1a 72 
𝐶𝑙𝑚𝑒𝑡ℎ𝑎𝑑𝑜𝑛𝑒(𝑐) =  𝐶𝑙𝑚𝑒𝑡ℎ𝑎𝑑𝑜𝑛𝑒_𝑏𝑎𝑠𝑎𝑙  × (1 − 𝑃 × [𝐷𝑒𝑡𝑜𝑚𝑖𝑑𝑖𝑛𝑒])       Eq 1b 73 
where S is the coefficient of moderation of detomidine Cl by detomidine plasma concentration 74 
[Detomidine]; p, coefficient of moderation of methadone Cl by [Detomidine].  75 
This replicated well the results from Gozalo-Marcilla et al. (2019c) with increased 76 
parameter precision. One consequence was that methadone better fitted within a 2-77 
compartment model instead of 3. Table 2 summarises the model improvement associated with 78 
inclusions of the two sources of non-linearity. Inclusion of a modulatory effect of detomidine 79 
on its own Cl and on methadone’s Cl (Fig 1b & Step 2 in Table 2) improved detomidine’s 80 
(OFV:1130 to 970) and methadone’s (OFV: 6727 to 6595) submodels fittings. Two problems 81 
remained with this model: i) the apparent increase in plasma concentrations of both drugs in 82 
all horses at the end of the infusion could not be fitted (concentrations consistently under-83 
estimated) and ii) consistent over-estimation of detomidine plasma concentrations after the 84 
smaller doses of detomidine.  85 
In this manuscript, we hypothesised a concentration-dependent effect of [Detomidine] 86 
on the distribution on both drugs (distributional clearance Cl2). [Detomidine] reduced 87 
unidirectionally the inter-compartment transfer rate constant from central to peripheral 88 
compartment, using an adaptation of a Michaelis-Menten model (equation 2), whereas the 89 
transfer rate constant from peripheral to central compartment did not change as a function of 90 
[Detomidine] (equation 2) (Fig 1c).  91 
The transfer rate constant from central to peripheral compartments for detomidine (CL2 92 
cp) and methadone (CL2m cp) was written as in equation 2a: 93 
𝐶𝑙2 𝑐→𝑝 =  
𝑉𝑚𝑎𝑥
(𝐾𝑚 + [𝐷𝑒𝑡𝑜𝑚𝑖𝑑𝑖𝑛𝑒]) 
⁄  and 𝐶𝑙2𝑚 𝑐→𝑝 =  
𝑉𝑚𝑎𝑥𝑚
(𝐾𝑚𝑚 + [𝐷𝑒𝑡𝑜𝑚𝑖𝑑𝑖𝑛𝑒]) 
⁄   94 
Eq 2a 95 
whereas the transfer rate constant from peripheral to central compartment for detomidine (CL2 96 
pc) and methadone (CL2m pc) remained as in equation 2b: 97 
𝐶𝑙2 𝑝→𝑐 =  
𝑉𝑚𝑎𝑥
(𝐾𝑚) 
⁄      and     𝐶𝑙2𝑚 𝑝→𝑐 =  
𝑉𝑚𝑎𝑥𝑚
(𝐾𝑚𝑚) 
⁄   Eq 2b 98 
Vmax and Vmaxm were the maximal transfer speed for detomidine and methadone respectively 99 
(expressed in µg kg-1 hr-1); Km and Kmm were the concentration of detomidine or methadone at 100 
half of Vmax. 101 
Inclusion of a dose-dependent effect on distributional Cl as represented in Fig 1c (Step 102 
3 in Table 2) improved model fit and OFVs for detomidine (OFV: 970 to 910) and methadone 103 
submodels (OFV: 6595 to 6543)]. Final parameters of this model are summarised in Table 3. 104 
Individual fits are presented in Figure 2.  Other solutions were explored and this specific one 105 
was the most satisfactory at the time of manuscript write-up, but one cannot exclude that a 106 
better solution could exist. 107 
In horses, α2-adrenergic receptor agonists, such as detomidine, increase systemic 108 
vascular resistance (SVR) and decreases heart rate (HR), therefore decreasing cardiac output 109 
(CO) (Yamashita et al., 2000); for drugs whose elimination are flow-dependent, Cl depends on 110 
liver perfusion and CO. Only few studies include concentration-dependent cardiovascular 111 
effects induced by a given drug in its PK model. Cardiac output influences distribution kinetics 112 
of alfentanil in conscious humans (Henthorn et al., 1992) and halothane-anaesthetized pigs 113 
(Kuipers et al., 1999); alfentanil’s depressant effects on CO can be counteracted by the 114 
analeptic doxapram, as increases distribution and elimination Cls of alfentanil (Roozekrans et 115 
al., 2017). Dutta et al. (2000) used HR as a surrogate for CO to improve the fit of 116 
dexmedetomidine PK in man, without relating dexmedetomidine concentrations directly to CO 117 
though. When dexmedetomidine was infused to isoflurane-anaesthetised cats, CO 118 
measurements obtained at steady state and included in a modified 2-compartment model helped 119 
modelling the effect of plasma dexmedetomidine concentrations on its own Cl (Pypendop et 120 
al., 2013). This was supported by the restoration of medetomidine’s Cl when administered with 121 
atipamezole in dogs (Salonen et al., 1995).  122 
Our research did not focus on concomitant CO changes. However, the knowledge of 123 
detomidine concentration-time profiles allowed comparison with other equine studies that 124 
reported concomitantly plasma concentrations and CO. Detomidine i.v. boli produced 125 
transitory vasoconstriction increasing SVR and arterial blood pressures, decreasing HR and 126 
CO (Yamashita et al., 2000); similar effects occurred when infused at four different target-127 
concentration rates (Daunt et al., 1993). In our CRI study (Fig 2, STUDY 2), the detomidine 128 
plateau concentrations increased from 2 to 3 µg/L for the low dose (2.5 µg/kg + 12.5 µg kg-1 129 
hr-1 over 2 hr, treatments F and H) and from 7 to 9 µg/L for the high dose (5 µg/kg + 25 µg kg-130 
1 hr-1 over 2 hr, treatments G and I). These concentrations are roughly in line with the two 131 
lowest target concentrations from Daunt et al. (1993) (infusion 1 and 2, respectively), 132 
demonstrating a concentration dependent effect of detomidine alone on CO (for all target 133 
plasma concentrations) and SVR (at higher target plasma concentrations). 134 
From our in vivo PK/PD modelling, data analysis showed non-linearity for both drugs 135 
at different levels of detomidine concentrations (Gozalo-Marcilla et al., 2019c). First, the 136 
empirical PK model included an effect of detomidine on the Cl of both drugs (Fig 1b), 137 
compatible with the observed effect at all plasma concentrations (Daunt et al., 1993). Second, 138 
the empirical model reduced the distribution of both drugs to the peripheral compartment at 139 
high plasma detomidine concentrations (Fig 1c), consistent with the vasoconstrictive effects of 140 
detomidine at higher plasma concentrations (Daunt et al., 1993). Detomidine-induced 141 
peripheral vasoconstriction is mediated via subtype receptors α2b in vascular smooth muscle 142 
(Link et al., 1996). As vasoconstriction occurs, there is a possibility that the “shrinking” 143 
peripheral distribution increases central organ perfusion, reducing the volume of distribution 144 
of other drugs (Bennett et al., 2017). These effects may be reduced by co-administering the 145 
antagonist MK-467, as reported in cats (Honkavaara et al., 2017; Pypendop et al., 2017) and 146 
horses (Pakkanen et al., 2015; de Vries et al., 2016). 147 
Some alternative strategies to model non-linearity were explored. Including a time 148 
dose-dependency in the expression of the volume of distribution is not allowed by basic 149 
function of Phoenix (due to circular referencing as concentrations are defined by 150 
amounts/volumes within a given compartment) but it is not impossible and could be 151 
programmed. The strategy from Roozerkans et al. (2017) to include the doxapram-induced 152 
increase in cardiac output in the expression of elimination and distributional clearances of 153 
alfentanil could not be tested in our setting but supports the concept that α2-adrenergic receptor 154 
agonists could affect elimination and distributional clearances in a PK model.  While we 155 
present a satisfactory solution to non-linearity, there may be better solutions that improve either 156 
the fitting of the data or the numerical stability of the model. Including an effect-site 157 
concentration of detomidine that could limit elimination and distribution clearances of both 158 
drugs through a pharmacodynamic function (Imax model for example) would be worth 159 
exploring (Roozerkans et al. 2017). 160 
To conclude, pooling the PK data from both studies i) helped confirming the non-161 
linearity of the elimination Cl and ii) allowed to explore hypotheses on the non-linearity of the 162 
distributional clearance (Michaelis-Menten equation) that could not be explored with only the 163 
first PK dataset (STUDY 1).  164 
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